返回 Agenda
Session Chair(s)
Thomas Metcalfe, MBA
Personalised Healthcare Ecosystems
F. Hoffmann-La Roche, Switzerland
Learning Objective : The participant will become aware of the: -difference in transparency between medicines and medical device legislation -absence of a link between pharmacogenomic tests used in clinical studies and clinical practice -limited implementation of pharmacogenomic testing in clinical practice guidelines
Speaker(s)
Regulatory Oversight of Companion Diagnostics - current and future plans
Shuna Mason
CMS Cameron McKenna LLP, United Kingdom
Head of Regulatory
Developing a Companion Diagnostic: How pharma and IVD companies need to co-operate, and liaise with authorities including case studies
Tim Kievits, MSC
VitrOmics, Netherlands
Director of Healthcare Innovation
Personalised medicine and pharmacogenomic tests: from label to clinical practice
Marjolein Weda, PHARMD, PHD
RIVM, Netherlands
Senior scientific officer